The Indian Pharma Market (IPM) is valued at Rs 6239 crores in April 2013. It has seen a growth of 9.3 per cent for the same month. Amongst the top 10, Zydus has registered a growth of 28 per cent, Sun Pharma at 25.8 per cent and Alkem at 16.8 per cent. 22 corporates have crossed the growth of IPM for the month of April 2013 amongst top 50. Sun Pharma has moved to number two position amongst corporates on MAT basis.
Amongst the top 50 corporates, Zydus has the highest growth of 28 per cent followed by Bharat Serums at 22.7 per cent and Ipca at 26.1 per cent. Amongst the 11-20 ranked companies Ipca shows high growth at 26.1 per cent followed by USV at 22.1 per cent and Intas at 21.6 per cent. Fourrts & Albert David moved up one rank over last time amongst the corporates in April 2013.
|
With Bonus Units at Full Value
|
||||||||
|
Val in Crs
|
Rank
|
MAT Apr -13
|
Apr-13
|
|||||
|
CORPORATE
|
MAT
|
MTH
|
Val (Cr)
|
MS%
|
GR%
|
Val (Cr)
|
MS%
|
GR%
|
|
IPM
|
71264
|
100.00
|
11.2
|
6239
|
100.00
|
9.3
|
||
|
Abbott + Abbott HC + Novo
|
1
|
1
|
4747
|
6.66
|
6.8
|
411
|
6.59
|
5.4
|
|
Sun Pharma
|
2
|
2
|
3550
|
4.98
|
21.0
|
331
|
5.31
|
25.8
|
|
Cipla
|
3
|
3
|
3543
|
4.97
|
6.2
|
323
|
5.17
|
4.8
|
|
Glaxo
|
4
|
6
|
3214
|
4.51
|
8.8
|
249
|
3.99
|
-9.0
|
|
Zydus + Biochem
|
5
|
4
|
3177
|
4.46
|
21.2
|
283
|
4.54
|
28.0
|
|
Ranbaxy
|
6
|
5
|
2940
|
4.13
|
6.7
|
253
|
4.05
|
4.9
|
|
Mankind
|
7
|
7
|
2582
|
3.62
|
21.6
|
219
|
3.51
|
8.9
|
|
Alkem + Cachet + Indchemie
|
8
|
8
|
2420
|
3.40
|
11.7
|
213
|
3.42
|
16.8
|
|
Pfizer + Wyeth
|
9
|
10
|
2231
|
3.13
|
10.7
|
180
|
2.88
|
-2.5
|
|
Lupin
|
10
|
9
|
2186
|
3.07
|
14.2
|
193
|
3.10
|
14.3
|
|
Macleods
|
11
|
12
|
1829
|
2.57
|
19.4
|
151
|
2.42
|
9.1
|
|
Intas
|
12
|
11
|
1763
|
2.47
|
18.9
|
166
|
2.67
|
21.6
|
|
Emcure + Zuventus
|
13
|
13
|
1674
|
2.35
|
12.6
|
146
|
2.34
|
9.8
|
|
Aristo
|
14
|
14
|
1642
|
2.30
|
10.4
|
144
|
2.31
|
11.3
|
|
Dr. Reddys
|
15
|
16
|
1567
|
2.20
|
12.2
|
135
|
2.16
|
9.0
|
|
Sanofi-Aventis + Universal
|
16
|
15
|
1546
|
2.17
|
9.5
|
136
|
2.18
|
6.8
|
|
Glenmark
|
17
|
17
|
1415
|
1.99
|
18.1
|
128
|
2.05
|
17.7
|
|
Micro + Bal
|
18
|
21
|
1292
|
1.81
|
6.3
|
107
|
1.72
|
4.3
|
|
Ipca
|
19
|
19
|
1283
|
1.80
|
16.3
|
119
|
1.91
|
26.1
|
|
USV
|
20
|
18
|
1265
|
1.78
|
21.2
|
120
|
1.93
|
22.1
|
Amongst upcoming corporates Corona Remedies has grown at 153.5 per cent, Akumentis at 28.3 per cent and Eris at 20.5 per cent. Ordain breaks into top 100.
From the therapy perspective, 10 therapies have outgrown the IPM growth. The anti-infective market has a growth of six per cent whereas respiratory market has seen an eight per cent growth. The anti-diabetic market has grown at 11.1 per cent and cardiac at 10.4 per cent in chronic business. Amongst the top 10 therapies, Neuro/CNS market has shown the highest growth at 13 per cent.
|
Val in Crs
|
||||
|
Super Group
|
MAT Apr 13
|
GR%
|
Mth Apr 13
|
GR%
|
|
IPM
|
71264
|
11.2
|
6239
|
9.3
|
|
ANTI-INFECTIVES
|
12587
|
9.0
|
1012
|
6.0
|
|
CARDIAC
|
8743
|
13.5
|
797
|
10.4
|
|
GASTRO INTESTINAL
|
8125
|
12.7
|
751
|
8.9
|
|
VITAMINS / MINERALS / NUTRIENTS
|
6327
|
12.1
|
569
|
8.9
|
|
RESPIRATORY
|
5406
|
7.7
|
429
|
8.0
|
|
PAIN / ANALGESICS
|
5272
|
8.4
|
464
|
9.1
|
|
GYNAECOLOGICAL
|
4637
|
8.8
|
408
|
6.9
|
|
ANTI DIABETIC
|
4625
|
15.4
|
417
|
11.1
|
|
NEURO / CNS
|
4345
|
11.3
|
398
|
13.0
|
|
DERMA
|
3737
|
11.9
|
328
|
11.9
|
|
OPHTHAL / OTOLOGICALS
|
1280
|
12.5
|
120
|
12.2
|
|
HORMONES
|
1230
|
16.9
|
108
|
14.6
|
|
OTHERS
|
966
|
16.0
|
89
|
21.1
|
|
BLOOD RELATED
|
873
|
8.3
|
78
|
-1.5
|
|
ANTI-NEOPLASTICS
|
871
|
15.0
|
87
|
27.2
|
|
VACCINES
|
868
|
6.3
|
74
|
2.7
|
|
ANTI MALARIALS
|
655
|
15.1
|
45
|
12.5
|
|
SEX STIMULANTS / REJUVENATORS
|
402
|
15.4
|
37
|
10.5
|
|
STOMATOLOGICALS
|
316
|
11.8
|
28
|
7.5
|
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech.
AWACS in AIOCD AWACS stands for Advanced Working, Action & Correction System – reflecting the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information. Accurate and faster information flows from the market will help clients grow topline and bottom-line.
Terminologies used
MAT – Moving Annual Total
MTH – MonthVal
(Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage
For more information, visit http://www.aiocd.net